![](https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1310938209.jpg?VersionId=jlB724V8e_.S74ugG4LH.VRm.LUO9vu8)
Alpha Cognition's delayed-release Alzheimer's drug Zunveyl passes muster with FDA
Amid an influx of new drugs targeting one of the believed root causes of Alzheimer’s disease, a new symptomatic med has hit the scene, courtesy of Vancouver’s Alpha Cognition. On Monday, the FDA gave a thumbs up to Alpha Cognition’s galantamine prodrug …